id,nct_id,group_type,title,description
20671985,NCT01589094,Experimental,Gemcitabine and Cisplatin (DD GC),This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
20673886,NCT01605227,Experimental,cabozantinib,Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
20673887,NCT01605227,Active Comparator,prednisone,Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
20675859,NCT01667419,Experimental,Cohort 1 Vemurafenib,"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks"
20675860,NCT01667419,Placebo Comparator,Cohort 1 Placebo,"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks"
20675861,NCT01667419,Experimental,Cohort 2 Vemurafenib,"Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks"
20675862,NCT01667419,Placebo Comparator,Cohort 2 Placebo,"Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks"
20676449,NCT01684878,Experimental,Part 1: Pertuzumab + Topotecan,"Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death."
20676450,NCT01684878,Experimental,Part 1: Pertuzumab + Paclitaxel,"Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death."
20676451,NCT01684878,Experimental,Part 2: Pertuzumab+Chemotherapy,"Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion."
20676452,NCT01684878,Placebo Comparator,Part 2: Placebo+Chemotherapy,"Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion."
20676827,NCT01695135,Experimental,Abiraterone acetate plus prednisone,NA
20676828,NCT01695135,Experimental,Placebo plus prednisone,NA
20677140,NCT01704651,Experimental,Alvimopan,"Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days."
20677141,NCT01704651,Placebo Comparator,Placebo,"Perioperative administration of placebo, at same dosing interval as study drug."
20680262,NCT01763164,Experimental,MEK162,NA
20680263,NCT01763164,Active Comparator,Dacarbazine,NA
20659607,NCT01227889,Experimental,GSK2118436,Subjects in this arm will receive GSK2118436 150 mg twice daily.
20659608,NCT01227889,Active Comparator,Dacarbazine (DTIC),Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
20659609,NCT01227889,Experimental,Crossover,Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
20683508,NCT01866319,Experimental,Ipilimumab,"Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months)."
20683509,NCT01866319,Experimental,Pembrolizumab Q2W,"Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months."
20683510,NCT01866319,Active Comparator,Pembrolizumab Q3W,"Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months."
20685952,NCT01920568,Experimental,Denosumab 120 mg,Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
20685953,NCT01920568,Experimental,Zoledronic acid 4 mg,Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
20687004,NCT01953913,Experimental,Afatinib,Patient will receive afatinib once daily
20687759,NCT01974752,Experimental,selumetinib 75mg twice daily,selumetinib 75mg twice daily in combination with dacarbazine.
20687760,NCT01974752,Placebo Comparator,placebo twice daily,placebo twice daily in combination with dacarbazine.
20689350,NCT02027428,Experimental,Abraxane + Best Supportive Care (BSC),"Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care."
20689351,NCT02027428,Other,Best Supportive Care (BSC),"Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only."
20689838,NCT02042443,Experimental,Trametinib,Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
20689839,NCT02042443,Experimental,Chemotherapy,Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
20691855,NCT02111577,Experimental,DCVAC/PCa with standard of care chemotherapy,Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
20691856,NCT02111577,Placebo Comparator,Placebo with standard of care chemotherapy,Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
20835986,NCT01122121,Experimental,Combined Radiotherapy and Hormone Therapy,"Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy."
20835987,NCT01122121,Active Comparator,Hormone Therapy alone,"Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin."
20665373,NCT01387269,Experimental,100 mg QD,Anamorelin HCL 100 mg will be administered daily
20665374,NCT01387269,Placebo Comparator,Placebo,Placebo tablets identical in appearance to active tablets; oral administration once daily
20665375,NCT01387282,Active Comparator,100 mg QD,"Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day."
20665376,NCT01387282,Placebo Comparator,Placebo,Placebo tablets identical in appearance to active tablets; oral administration once daily
20696539,NCT02279732,Experimental,Arm 1: Carboplatin + Paclitaxel + Ipilimumab,Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
20696540,NCT02279732,Experimental,Arm 2: Carboplatin + Paclitaxel + Placebo,Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
20697210,NCT02302807,Experimental,Arm A: Atezolizumab,Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
20697211,NCT02302807,Active Comparator,"Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)","Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity."
20697404,NCT02311907,Experimental,"Arm I (glutathione, carboplatin)","Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes."
20697405,NCT02311907,Placebo Comparator,"Arm II (placebo, paclitaxel)","Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes."
20698856,NCT02364999,Experimental,Bevacizumab-Pfizer,Bevacizumab-Pfizer plus paclitaxel and carboplatin
20698857,NCT02364999,Active Comparator,Bevacizumab-EU,Bevacizumab-EU plus paclitaxel and carboplatin
20698888,NCT02366143,Experimental,Arm A (Atezolizumab+Paclitaxel+Carboplatin),"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit."
20698889,NCT02366143,Experimental,Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin),"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase."
20698890,NCT02366143,Active Comparator,Arm C (Bevacizumab+Paclitaxel+Carboplatin),"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death."
20698934,NCT02367781,Experimental,Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin),"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit."
20698935,NCT02367781,Active Comparator,Arm B (Nab-Paclitaxel+Carboplatin),"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression."
20699655,NCT02395172,Experimental,Avelumab,NA
20699656,NCT02395172,Active Comparator,Docetaxel,NA
20716505,NCT01721772,Experimental,"Nivolumab, 3 mg/kg","Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."
20716506,NCT01721772,Active Comparator,"Dacarbazine, 1000 mg/m^2","Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."
20700341,NCT02421588,Experimental,Arm A,lurbinectedin (PM01183)
20700342,NCT02421588,Active Comparator,Arm B,pegylated liposomal doxorubicin~OR~topotecan
20701704,NCT02474355,Experimental,AZD9291,"Single arm of AZD9291, starting dose of 80mg"
20665694,NCT01395914,Experimental,100 mg QD,"100 mg yellow coated, oval tablet; oral administration once daily"
20665695,NCT01395914,Placebo Comparator,Placebo,Placebo tablets identical in appearance to active tablets; oral administration once daily
20703437,NCT02545075,Experimental,Ipilimumab,"Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression"
20703438,NCT02545075,Experimental,Dacarbazine,"IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)"
20664168,NCT01351415,Experimental,Bevacizumab + Standard of Care,"Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."
20664169,NCT01351415,Active Comparator,Standard of Care,Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
20664306,NCT01355497,Experimental,GTx-024 3mg once daily,subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial
20664307,NCT01355497,Placebo Comparator,placebo,subjects will be randomized to receive matching placebo once daily for the duration of the trial
20721453,NCT02905266,Experimental,Nivolumab and Ipilimumab Concomitant Administration,Followed by Nivolumab monotherapy
20721454,NCT02905266,Experimental,Nivolumab and Ipilimumab Sequential Administration,Followed by Nivolumab monotherapy
20729205,NCT03296163,Experimental,MB02 (Bevacizumab Biosimilar Drug),MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
20729206,NCT03296163,Active Comparator,EU-approved Avastin®,EU-approved Avastin® + Carboplatin/Paclitaxel
20729693,NCT03329911,Active Comparator,EU Avastin®,"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
20729694,NCT03329911,Experimental,BAT1706,"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
20742015,NCT00003120,Active Comparator,paclitaxel 3 cycles,paclitaxel given for 3 cycles
20742016,NCT00003120,Experimental,paclitaxel for 12 cycles,paclitaxel given for 12 cycles
20661765,NCT01285609,Experimental,Ipilimumab + Paclitaxel and Carboplatin,"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
20661766,NCT01285609,Placebo Comparator,Placebo + Paclitaxel and Carboplatin,"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
20751277,NCT00087711,Experimental,A,NA
20751278,NCT00087711,Active Comparator,B,NA
20751860,NCT00106691,Experimental,toremifene 20mg,NA
20751861,NCT00106691,Placebo Comparator,Placebo,NA
20669492,NCT01515189,Experimental,Arm 1: Ipilimumab (3 mg/kg),"Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity"
20669493,NCT01515189,Experimental,Arm 2: Ipilimumab (10 mg/kg),"Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity"
20762653,NCT00312013,No Intervention,No Nadroparin,Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
20762654,NCT00312013,Experimental,Nadroparin,"Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment."
20766211,NCT00378690,Active Comparator,Continuous Androgen Deprivation (CAD),NA
20766212,NCT00378690,Experimental,Intermittent Androgen Deprivation (IAD),NA
20768880,NCT00436839,Experimental,1,"Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle"
20768881,NCT00436839,Active Comparator,2,"Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle"
20662574,NCT01307397,Experimental,Vemurafenib,"Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first."
20662604,NCT01308567,Experimental,Cabazitaxel 25 mg/m^2,"Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal."
20662605,NCT01308567,Experimental,Cabazitaxel 20 mg/m^2,"Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal."
20662606,NCT01308567,Active Comparator,Docetaxel 75 mg/m^2,"Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal."
20662607,NCT01308580,Experimental,Cabazitaxel 20 mg/m^2,"Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles."
20662608,NCT01308580,Experimental,Cabazitaxel 25 mg/m^2,"Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles."
20799976,NCT02200614,Experimental,Darolutamide (BAY1841788),"Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg."
20799977,NCT02200614,Placebo Comparator,Placebo,Participants received matching placebo 2 tablets twice daily with food.
20804283,NCT00806923,Experimental,1,NA
20804284,NCT00806923,Experimental,2,NA
20804285,NCT00806923,Placebo Comparator,3,NA
20875666,NCT00330759,Active Comparator,zoledronic acid,denosumab placebo with active zoledronic acid
20875667,NCT00330759,Experimental,denosumab,active denosumab with zoledronic acid placebo
20825423,NCT01011751,Experimental,Cyproterone acetate,"Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks."
20825424,NCT01011751,Experimental,Medroxyprogesterone acetate,"Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks."
20825425,NCT01011751,Experimental,Venlafaxine,"Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks."
20908442,NCT02663908,Experimental,Degarelix,NA
20908443,NCT02663908,Active Comparator,Leuprolide,NA
20908887,NCT02367794,Experimental,Arm A: Atezolizumab + Paclitaxel + Carboplatin,"The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant."
20908888,NCT02367794,Experimental,Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin,"The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant."
20908889,NCT02367794,Active Comparator,Arm C: Nab-Paclitaxel + Carboplatin,"The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care."
20923983,NCT01837251,No Intervention,Control Arm,Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
20923984,NCT01837251,Experimental,Research Arm,Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
20660054,NCT01239732,Experimental,Bevacizumab + Paclitaxel + Carboplatin,"Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first)."
20939810,NCT01964170,Experimental,ASP3550 PART 1 and PART 2,Part 1 for 1 year treatment and Part 2 for an extended period of treatment
20939811,NCT01964170,Active Comparator,Goserelin,part 1 for 1 year treatment
20660237,NCT01245062,Experimental,GSK1120212,MEK inhibitor
20660238,NCT01245062,Active Comparator,Chemotherapy,Investigator Choice of DTIC or paclitaxel
20660239,NCT01245062,Experimental,Crossover,MEK inhibitor after documented progression on Chemotherapy Arm
20297759,NCT02142738,Experimental,Pembrolizumab,"Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles."
20297760,NCT02142738,Active Comparator,Paclitaxel+Carboplatin,"Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment."
20297761,NCT02142738,Active Comparator,Pemetrexed+Carboplatin,"Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment."
20297762,NCT02142738,Active Comparator,Pemetrexed+Cisplatin,"Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment."
20297763,NCT02142738,Active Comparator,Gemcitabine+Carboplatin,"Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment."
20297764,NCT02142738,Active Comparator,Gemcitabine+Cisplatin,"Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment."
20663079,NCT01322490,Experimental,PROSTVAC-V/F-TRICOM + GM-CSF,PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF
20663080,NCT01322490,Experimental,PROSTVAC-V/F-TRICOM + GM-CSF placebo,PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF placebo
20663081,NCT01322490,Placebo Comparator,Placebo Control,PROSTVAC V/F Placebo + GM-CSF Placebo
20414120,NCT02106546,Experimental,Veliparib + Carboplatin + Paclitaxel,"Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression."
20414121,NCT02106546,Placebo Comparator,Placebo + Carboplatin + Paclitaxel,"Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression."
20309397,NCT03180307,Sham Comparator,no fluorescent imaging,"Patient injected with OTL38, but does not undergo fluorescent imaging"
20309398,NCT03180307,Experimental,near infrared imaging arm,Patient injected with OTL38 and undergoes near infrared imaging
20329266,NCT01578655,Experimental,Cabazitaxel plus Custirsen,"cabazitaxel, prednisone, and custirsen sodium"
20329267,NCT01578655,Active Comparator,Cabazitaxel,cabazitaxel and prednisone
20330445,NCT01204749,Experimental,AMG 386,Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
20330446,NCT01204749,Placebo Comparator,AMG 386 Placebo,Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
20334035,NCT00382811,Experimental,1,Daily Phenoxodiol + weekly carboplatin
20334036,NCT00382811,Active Comparator,2,Daily phenoxodiol placebo + weekly carboplatin
20570889,NCT03273153,Experimental,Cobimetinib and Atezolizumab,"Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle."
20570890,NCT03273153,Active Comparator,Pembrolizumab,"Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first."
20654125,NCT01106040,Experimental,"Lymphoseek, Lymphatic mapping, Injection",NA
20608969,NCT00003644,Experimental,"Carboplatin, paclitaxel, low dose paclitaxel","carboplatin, paclitaxel followed by low dose paclitaxel 4 weeks later"
20608970,NCT00003644,Active Comparator,"Carboplatin, paclitaxel","carboplatin, paclitaxel"
20610791,NCT00011986,Active Comparator,Arm I,Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
20610792,NCT00011986,Experimental,Arm II,Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
20610793,NCT00011986,Experimental,Arm III,"Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I."
20610794,NCT00011986,Experimental,Arm IV,Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
20610795,NCT00011986,Experimental,Arm V,Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
20610922,NCT00033540,Experimental,Capecitabine + Gemcitabine,"Capecitabine 650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days"
20611171,NCT00050960,Experimental,bexarotene with carboplatin and paclitaxel,NA
20611172,NCT00050960,Experimental,carboplatin and paclitaxel,NA
20611259,NCT00055601,Experimental,Pelvic RT + paclitaxel + cisplatin,"Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin."
20611260,NCT00055601,Experimental,Pelvic RT + fluorouracil + cisplatin,"Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin."
20611266,NCT00056407,Placebo Comparator,Placebo Arm,Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
20611267,NCT00056407,Experimental,dustasteride arm,Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
20611428,NCT00065442,Placebo Comparator,APC-Placebo,NA
20611429,NCT00065442,Active Comparator,Sipuleucel-T,NA
20612005,NCT00089674,Experimental,AMG 162,NA
20612006,NCT00089674,Placebo Comparator,Placebo,NA
20612065,NCT00091572,Experimental,A,"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
20612066,NCT00091572,Active Comparator,B,"dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks"
20612142,NCT00094653,Active Comparator,1,Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
20612143,NCT00094653,Experimental,2,MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
20612144,NCT00094653,Active Comparator,3,MDX-010 (ipilimumab) + Placebo
20612172,NCT00095199,Experimental,Cetuximab & Pemetrexed,NA
20612173,NCT00095199,Active Comparator,Pemetrexed,NA
20612174,NCT00095199,Experimental,Cetuximab & Docetaxel,NA
20612175,NCT00095199,Active Comparator,Docetaxel,NA
20612371,NCT00102804,Experimental,Pemetrexed and Best Supportive Care,NA
20612372,NCT00102804,Placebo Comparator,Placebo and Best Supportive Care,NA
20612626,NCT00111007,Experimental,"Sorafenib (Nexavar, BAY43-9006)","Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period."
20612627,NCT00111007,Active Comparator,Carboplatin/Paclitaxel (C/P),"Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period."
20612735,NCT00113607,Experimental,DOXIL + trabectedin,Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
20612736,NCT00113607,Active Comparator,DOXIL,Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
20613534,NCT00148798,Experimental,Cetuximab plus chemotherapy,cetuximab + cisplatin + vinorelbine
20613535,NCT00148798,Active Comparator,Chemotherapy alone,cisplatin + vinorelbine alone
20613930,NCT00172042,Experimental,Zoledronic acid,Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
20613931,NCT00172042,Other,Control,"No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed."
20615040,NCT00234039,Experimental,Intravesical Gemcitabine,NA
20616297,NCT00286091,Placebo Comparator,Placebo,Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
20616298,NCT00286091,Experimental,Denosumb,Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
20617714,NCT00312377,Active Comparator,1,Docetaxel monotherapy
20617715,NCT00312377,Experimental,2,Vandetanib + Docetaxel
20618000,NCT00321620,Active Comparator,zoledronic acid,NA
20618001,NCT00321620,Experimental,denosumab,NA
20618066,NCT00322452,Experimental,1,gefitinib
20618067,NCT00322452,Active Comparator,2,Carboplatin/Paclitaxel
20618126,NCT00324155,Experimental,Arm A: Ipilimumab and Dacarbazine,In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
20618127,NCT00324155,Active Comparator,Arm B: Placebo and Dacarbazine,NA
20620331,NCT00373425,Experimental,Erlotinib,"Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity."
20620332,NCT00373425,Placebo Comparator,Placebo,"Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity."
20620875,NCT00390806,Experimental,topotecan plus radiation,"topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy."
20620876,NCT00390806,Active Comparator,Whole brain radiation,Whole brain radiation 3 Gy/day for 10 days
20621677,NCT00412971,Active Comparator,Hexvix cystoscopy group,NA
20621678,NCT00412971,Other,White light,Standard White light cystoscopy
20621828,NCT00417079,Active Comparator,Mitoxantrone + Prednisone,Mitoxantrone + Prednisone
20621829,NCT00417079,Experimental,Cabazitaxel + Prednisone,Cabazitaxel + Prednisone
20622944,NCT00445601,Experimental,Arm I,Patients receive intravesical gemcitabine hydrochloride over 1 hour.
20622945,NCT00445601,Placebo Comparator,Arm II,Patients receive intravesical placebo over 1 hour.
20623062,NCT00449033,Experimental,"Sorafenib (Nexavar, BAY43-9006) + GC","Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met."
20623063,NCT00449033,Placebo Comparator,Placebo + GC,"Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met."
20623461,NCT00461591,Experimental,Apaziquone,TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
20623462,NCT00461591,Placebo Comparator,Placebo,TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
20624956,NCT00506155,Experimental,Neoadjuvant Chemotherapy with M-VAC + Avastin,Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m^2 by vein over 4 hours. Doxorubicin 30 mg/m^2 by vein over 15 minutes. Methotrexate 30 mg/m^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m^2 by vein over 30 minutes.
20625436,NCT00519285,Placebo Comparator,Placebo,Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
20625437,NCT00519285,Experimental,Aflibercept,Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
20625908,NCT00532155,Experimental,Placebo/Docetaxel,"Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal."
20625909,NCT00532155,Placebo Comparator,Aflibercept/Docetaxel,"Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal."
20626259,NCT00540514,Experimental,Albumin-bound paclitaxel + Carboplatin,"Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent."
20626260,NCT00540514,Active Comparator,Paclitaxel + Carboplatin,"Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent."
20626822,NCT00554229,Experimental,ZD4054,ZD4054 10 mg oral tablet once daily
20626823,NCT00554229,Placebo Comparator,Placebo,"Matching Placebo, oral tablets once daily"
20626880,NCT00556322,Experimental,1,NA
20626881,NCT00556322,Active Comparator,2,NA
20626896,NCT00556712,Experimental,Erlotinib,"Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity."
20626897,NCT00556712,Placebo Comparator,Placebo,"Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity."
20631354,NCT00598806,Experimental,Apaziquone,TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
20631355,NCT00598806,Placebo Comparator,Placebo,TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
20632157,NCT00617669,Active Comparator,Placebo + Docetaxel,placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
20632158,NCT00617669,Experimental,ZD4054 + Docetaxel,ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
20632562,NCT00626431,Experimental,Leuprolide acetate - Formulation A,"Leuprolide acetate 45 mg, 6-month depot"
20632563,NCT00626431,Experimental,Leuprolide acetate - Formulation B,"Leuprolide acetate, 45 mg, 6-month depot"
20632952,NCT00636168,Active Comparator,A,NA
20632953,NCT00636168,Placebo Comparator,B,NA
20633044,NCT00638690,Experimental,Abiraterone acetate plus prednisone/prednisolone,NA
20633045,NCT00638690,Placebo Comparator,Placebo plus prednisone/prednisolone,NA
20633592,NCT00656136,Placebo Comparator,Placebo,Patients receive placebo once daily
20633593,NCT00656136,Experimental,BIBW 2992,Patients receive BIBW 2992 tablets once daily
20633818,NCT00661609,Experimental,AZD4877,Single agent AZD4877
20634878,NCT00686959,Experimental,Arm A: Pemetrexed + Cisplatin and TRT,"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles~Concurrent Phase:~Pemetrexed: 500 milligrams per meter squared (mg/m^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.~Cisplatin: 75 mg/m^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray [Gy] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.~Consolidation Phase:~Pemetrexed: 500 mg/m^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
20634879,NCT00686959,Active Comparator,Arm B: Etoposide + Cisplatin and TRT,"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles~Concurrent Phase:~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m^2, IV on Days1, 8, 29, and 36~Consolidation Phase options:~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
20635335,NCT00699751,Experimental,"Radium-223 dichloride (Xofigo, BAY88-8223)",Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
20635336,NCT00699751,Placebo Comparator,Placebo,Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
20637220,NCT00744497,Placebo Comparator,Placebo,"Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily"
20637221,NCT00744497,Active Comparator,Dasatinib,"Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily"
20638298,NCT00769704,Active Comparator,GM-CSF,"Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months."
20638299,NCT00769704,Experimental,Talimogene Laherparepvec,"Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months."
20639544,NCT00801242,Experimental,Degarelix 240 mg / 80 mg,NA
20639698,NCT00805194,Experimental,BIBF 1120 plus docetaxel,BIBF 1120 2 times daily along with standard therapy of docetaxel
20639699,NCT00805194,Placebo Comparator,Placebo plus docetaxel,Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
20657280,NCT01168973,Experimental,Ramucirumab + Docetaxel,NA
20657281,NCT01168973,Placebo Comparator,Placebo + Docetaxel,NA
20641585,NCT00833248,Experimental,Degarelix 240 mg/80 mg,"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively."
20641586,NCT00833248,Active Comparator,Goserelin (3.6 mg) + bicalutamide (50 mg),"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
20641783,NCT00838201,Experimental,Arm 1,NA
20642641,NCT00861614,Active Comparator,Ipilimumab,NA
20642642,NCT00861614,Placebo Comparator,Placebo,NA
20642744,NCT00864253,Experimental,ABI-007,"Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks."
20642745,NCT00864253,Active Comparator,Dacarbazine,Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
20643566,NCT00887198,Placebo Comparator,Placebo + prednisone,Placebo plus prednisone
20643567,NCT00887198,Experimental,Abiraterone + prednisone,Abiraterone acetate plus prednisone
20644810,NCT00925600,Placebo Comparator,Placebo,Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
20644811,NCT00925600,Experimental,Denosumab,Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
20645701,NCT00946920,Experimental,Degarelix 240 mg/480 mg,NA
20645702,NCT00946920,Active Comparator,Goserelin acetate,NA
20657824,NCT01183858,Experimental,Erlotinib 150 mg,Erlotinib 150 mg single daily oral dose until disease progression.
20657825,NCT01183858,Experimental,Erlotinib 300 mg,Erlotinib 300 mg single daily oral dose until disease progression.
20646790,NCT00974311,Experimental,Enzalutamide,Formerly MDV3100
20646791,NCT00974311,Placebo Comparator,Placebo,NA
20646952,NCT00978250,Experimental,5-Fluro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU),FdCyd (100 mg/m(2)) + THU (350 mg/m(2)) administered 5 days/week for 2 weeks in 28-day cycles
20647415,NCT00988208,Experimental,"Docetaxel, Prednisone, Lenalidomide (DPL)",25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
20647416,NCT00988208,Experimental,Docetaxel and Prednisone (DP),Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
20658947,NCT01212991,Experimental,Enzalutamide,NA
20658948,NCT01212991,Placebo Comparator,Placebo,NA
20648155,NCT01006980,Experimental,Vemurafenib,NA
20648156,NCT01006980,Active Comparator,Dacarbazine,NA
20648485,NCT01015118,Experimental,BIBF 1120,patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
20648486,NCT01015118,Placebo Comparator,Placebo,patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
20648663,NCT01020448,Experimental,Triptorelin (Decapeptyl®) 22.5 mg,NA
20649823,NCT01031420,Experimental,dose dense MVAC,standard doses of MVAC given every 14 days x 3.
20651767,NCT01040780,Experimental,Icotinib,125 mg three times daily (375 mg per day) by mouth
20651768,NCT01040780,Active Comparator,Gefitinib,250 mg every 24 hours by mouth
20652352,NCT01057810,Experimental,Ipilimumab,NA
20652353,NCT01057810,Placebo Comparator,Placebo,NA
20658193,NCT01193244,Experimental,Orteronel + prednisone,NA
20658194,NCT01193244,Placebo Comparator,Placebo + prednisone,NA
20658195,NCT01193257,Experimental,Orteronel + prednisone,NA
20658196,NCT01193257,Placebo Comparator,Placebo + prednisone,NA
20653333,NCT01085136,Active Comparator,Investigator's choice of chemotherapy,Patients will be treated with investigator's choice of chemotherapy
20653334,NCT01085136,Experimental,BIBW 2992 and Paclitaxel,Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
